NCT04574817 is a Phase 2 clinical trial of HX008 in Anaplastic Thyroid Cancer, sponsored by Taizhou Hanzhong biomedical co. LTD.

Who is sponsoring NCT04574817?

NCT04574817 is sponsored by Taizhou Hanzhong biomedical co. LTD.

What drugs are being tested in NCT04574817?

Interventions in NCT04574817: HX008.

What condition does NCT04574817 study?

NCT04574817 studies Anaplastic Thyroid Cancer.

Is NCT04574817 still recruiting?

NCT04574817 is currently status unknown. Last updated 5 October 2020.

Last reviewed 2020-10-05 · How we verify

NCT04574817

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Status unknown Phase 2 Last updated 5 October 2020

What this trial tests

Phase 2 trial testing HX008 in Anaplastic Thyroid Cancer in 66 participants. Status unknown.

Timeline

28 December 2020

Primary endpoint
30 May 2022

30 May 2023

Quick facts

Lead sponsor	Taizhou Hanzhong biomedical co. LTD
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	28 December 2020
Primary completion	30 May 2022
Estimated completion	30 May 2023
Sites	1 location across China

Drugs / interventions tested

HX008 — full drug profile →

Conditions studied

Anaplastic Thyroid Cancer — all drugs for Anaplastic Thyroid Cancer →

Sponsor

Taizhou Hanzhong biomedical co. LTD — full company profile →

Who can join

18 and older, any sex, with Anaplastic Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are currently no target therapies approved for treatment of anaplastic thyroid cancer (ATC), leading to a clear need for improving therapy for ATC. This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with metastatic or locally advanced anaplastic thyroid cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors.
Liu R, Li W, Meng Y, Gao S, et al · · 2021 · cited 8× · PMID 34158838 · DOI 10.1177/17588359211020528
Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
Gao X, Hong C, Xie Y, Zeng X. · · 2023 · cited 7× · PMID 37007127 · DOI 10.3389/fonc.2023.1103147

Verify or expand the search:

Other trials of HX008

Trials testing the same drug.

NCT07054307 — MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinom · Phase 1 · recruiting
NCT05652894 — A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal · Phase 3 · not yet recruiting
NCT04741165 — Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC · Phase 2 · unknown
NCT04750083 — HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or · Phase 2, PHASE3 · unknown
NCT04738630 — Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer · Phase 2 · unknown

Other recruiting trials for Anaplastic Thyroid Cancer

Currently open trials in the same condition.

NCT06902376 — XL092 and Cemiplimab in BRAF WT Thyroid Cancer · Phase 1 · recruiting
NCT06374602 — Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer · Phase 2 · recruiting
NCT06362694 — Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF · Phase 2 · recruiting
NCT06079333 — NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) · Phase 2 · recruiting
NCT04420754 — Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer · Phase 1 · active not recruiting

Other Taizhou Hanzhong biomedical co. LTD trials

Trials by the same sponsor.

NCT05647954 — A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage · Phase 3 · unknown
NCT05652894 — A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal · Phase 3 · not yet recruiting
NCT04741165 — Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC · Phase 2 · unknown
NCT04738630 — Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer · Phase 2 · unknown
NCT04750083 — HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or · Phase 2, PHASE3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04574817 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taizhou Hanzhong biomedical co. LTD
Last refreshed: 5 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04574817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing